SPOTLIGHT: Ranbaxy drugs re-approved

The World Health Organization has returned seven of Ranbaxy's drugs to its list of pre-qualified HIV medications. The drugs had been removed last year due to discrepancies in clinical test data. Story

Suggested Articles

As Relay looks to enter the clinic in 2020, the company is adding a trio of biopharma vets to its leadership team.

A phase 3 trial of Myovant Sciences’ relugolix in prostate cancer has met its primary endpoint, teeing the company up to file for FDA approval.

The Medicines Company, fresh from its turn at the AHA this weekend, has seen its shares jump on growing rumors that Novartis wants to acquire it.